Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Why Should Clinicians Be Concerned About Prescribing Compounded Hormones for Menopausal Women?

Pinkerton JV.

J Womens Health (Larchmt). 2018 Jun 29. doi: 10.1089/jwh.2018.7215. [Epub ahead of print] No abstract available.

PMID:
29957102
2.

Not time to abandon use of local vaginal hormone therapies.

Pinkerton JV, Kaunitz AM, Manson JE.

Menopause. 2018 Jun 11. doi: 10.1097/GME.0000000000001142. [Epub ahead of print] No abstract available.

PMID:
29894370
3.

Hormone Therapy: Key Points From NAMS 2017 Position Statement.

Pinkerton JV.

Clin Obstet Gynecol. 2018 Jun 8. doi: 10.1097/GRF.0000000000000383. [Epub ahead of print]

PMID:
29889667
4.

Managing Menopause by Combining Evidence With Clinical Judgement.

Kaunitz AM, Pinkerton JV.

Clin Obstet Gynecol. 2018 Jun 8. doi: 10.1097/GRF.0000000000000387. [Epub ahead of print] No abstract available.

PMID:
29889666
5.

The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.

Simon JA, Goldstein I, Kim NN, Davis SR, Kellogg-Spadt S, Lowenstein L, Pinkerton JV, Stuenkel CA, Traish AM, Archer DF, Bachmann G, Goldstein AT, Nappi RE, Vignozzi L.

Menopause. 2018 Jul;25(7):837-847. doi: 10.1097/GME.0000000000001138.

PMID:
29870471
6.

Tissue-selective Estrogen Complex for Menopausal Hormone Therapy.

Pinkerton JV.

Clin Obstet Gynecol. 2018 May 25. doi: 10.1097/GRF.0000000000000386. [Epub ahead of print]

PMID:
29851863
7.

Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health.

Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, Kaunitz AM, Krychman ML, Parish SJ, Partridge AH, Pinkerton JV, Rowen TS, Shapiro M, Simon JA, Goldfarb SB, Kingsberg SA.

Menopause. 2018 Jun;25(6):596-608. doi: 10.1097/GME.0000000000001121.

PMID:
29762200
8.

Concern about US Preventive Services Task Force recommendation on hormone therapy for the primary prevention of chronic conditions in postmenopausal women.

Pinkerton JV, Kaunitz AM, Manson JE.

Menopause. 2018 May;25(5):476. doi: 10.1097/GME.0000000000001100. No abstract available.

PMID:
29658911
9.

Hormonal contraception and risk of breast cancer: a closer look.

Kaunitz AM, Pinkerton JV, Manson JE.

Menopause. 2018 May;25(5):477-479. doi: 10.1097/GME.0000000000001101. No abstract available.

PMID:
29557848
10.

Management of Menopausal Symptoms for Women Who Are at High Risk of Thrombosis.

Pinkerton JV, James AH.

Clin Obstet Gynecol. 2018 Jun;61(2):260-268. doi: 10.1097/GRF.0000000000000358.

PMID:
29419532
11.

Screening mammography for average-risk women.

Kaunitz AM, Pinkerton JV, Ghate SV, Wolf AMD.

Menopause. 2018 Mar;25(3):343-345. doi: 10.1097/GME.0000000000001026.

PMID:
29257034
12.

Menopause 25th anniversary: past success and future direction.

Schiff I, Utian WH, Pinkerton JV.

Menopause. 2018 Jan;25(1):1-3. doi: 10.1097/GME.0000000000001038. No abstract available.

PMID:
29251683
13.

Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.

Simon JA, Altomare C, Cort S, Jiang W, Pinkerton JV.

J Womens Health (Larchmt). 2018 Jan;27(1):14-23. doi: 10.1089/jwh.2017.6385. Epub 2017 Oct 24.

14.

Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance.

Pinkerton JV, Kaunitz AM, Manson JE.

Menopause. 2017 Dec;24(12):1329-1332. doi: 10.1097/GME.0000000000000996. No abstract available.

PMID:
29040220
15.

Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors.

Santen RJ, Stuenkel CA, Davis SR, Pinkerton JV, Gompel A, Lumsden MA.

J Clin Endocrinol Metab. 2017 Oct 1;102(10):3647-3661. doi: 10.1210/jc.2017-01138. Review.

PMID:
28934376
16.

Changing the conversation about hormone therapy.

Pinkerton JV.

Menopause. 2017 Sep;24(9):991-993. doi: 10.1097/GME.0000000000000965. No abstract available.

PMID:
28763394
17.

Changing the conversation about hormone therapy.

Pinkerton JV.

Climacteric. 2017 Aug;20(4):293-295. doi: 10.1080/13697137.2017.1346380. Epub 2017 Jul 4. No abstract available.

PMID:
28675703
18.

Safety and benefit considerations for menopausal hormone therapy.

Pickar JH, Archer DF, Kagan R, Pinkerton JV, Taylor HS.

Expert Opin Drug Saf. 2017 Aug;16(8):941-954. doi: 10.1080/14740338.2017.1343298. Epub 2017 Jun 30. Review.

PMID:
28664754
19.

Hot flush frequency and severity at baseline as predictors of time to transient and stable treatment success: pooled analysis of two CE/BZA studies.

Pinkerton JV, Bushmakin AG, Bobula J, Lavenberg J, Komm BS, Abraham L.

Menopause. 2017 Dec;24(12):1378-1385. doi: 10.1097/GME.0000000000000918.

PMID:
28654628
20.

Time to first occurrence of breast pain and vaginal bleeding in phase 3 trials of CE/BZA.

Pinkerton JV, Bushmakin AG, Bobula J, Lavenberg J, Komm BS, Abraham L.

Menopause. 2017 Dec;24(12):1372-1377. doi: 10.1097/GME.0000000000000935.

PMID:
28609389
21.

Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning.

Pinkerton JV, Bushmakin AG, Komm BS, Abraham L.

Maturitas. 2017 Jun;100:57-63. doi: 10.1016/j.maturitas.2017.03.315. Epub 2017 Mar 22.

PMID:
28539177
22.

Time to transient and stable reductions in hot flush frequency in postmenopausal women using conjugated estrogens/bazedoxifene.

Pinkerton JV, Bushmakin AG, Abraham L, Komm BS, Bobula J.

Menopause. 2017 Sep;24(9):1011-1016. doi: 10.1097/GME.0000000000000888.

PMID:
28463874
23.

Role for NLRP3 Inflammasome-mediated, IL-1β-Dependent Responses in Severe, Steroid-Resistant Asthma.

Kim RY, Pinkerton JW, Essilfie AT, Robertson AAB, Baines KJ, Brown AC, Mayall JR, Ali MK, Starkey MR, Hansbro NG, Hirota JA, Wood LG, Simpson JL, Knight DA, Wark PA, Gibson PG, O'Neill LAJ, Cooper MA, Horvat JC, Hansbro PM.

Am J Respir Crit Care Med. 2017 Aug 1;196(3):283-297. doi: 10.1164/rccm.201609-1830OC.

PMID:
28252317
24.

Inflammasomes in the lung.

Pinkerton JW, Kim RY, Robertson AAB, Hirota JA, Wood LG, Knight DA, Cooper MA, O'Neill LAJ, Horvat JC, Hansbro PM.

Mol Immunol. 2017 Jun;86:44-55. doi: 10.1016/j.molimm.2017.01.014. Epub 2017 Jan 24. Review.

PMID:
28129896
25.

Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women.

Abraham L, Bushmakin AG, Dragon E, Komm BS, Pinkerton JV.

Maturitas. 2016 Dec;94:173-179. doi: 10.1016/j.maturitas.2016.09.010. Epub 2016 Sep 16.

PMID:
27823739
26.

Timing and persistence of effect of conjugated estrogens/bazedoxifene in postmenopausal women.

Kagan R, Komm BS, Ryan KA, Lavenberg J, Yu CR, Pinkerton JV.

Menopause. 2016 Nov;23(11):1204-1213.

PMID:
27433860
27.

Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.

Archer DF, Freeman EW, Komm BS, Ryan KA, Yu CR, Mirkin S, Pinkerton JV.

J Womens Health (Larchmt). 2016 Nov;25(11):1102-1111. Epub 2016 Sep 27.

PMID:
27676118
28.

Elucidating novel disease mechanisms in severe asthma.

Kim RY, Rae B, Neal R, Donovan C, Pinkerton J, Balachandran L, Starkey MR, Knight DA, Horvat JC, Hansbro PM.

Clin Transl Immunology. 2016 Jul 15;5(7):e91. doi: 10.1038/cti.2016.37. eCollection 2016 Jul. Review.

29.

MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2.

Kim RY, Horvat JC, Pinkerton JW, Starkey MR, Essilfie AT, Mayall JR, Nair PM, Hansbro NG, Jones B, Haw TJ, Sunkara KP, Nguyen TH, Jarnicki AG, Keely S, Mattes J, Adcock IM, Foster PS, Hansbro PM.

J Allergy Clin Immunol. 2017 Feb;139(2):519-532. doi: 10.1016/j.jaci.2016.04.038. Epub 2016 Jun 10.

30.

Relationship between changes in vasomotor symptoms and changes in menopause-specific quality of life and sleep parameters.

Pinkerton JV, Abraham L, Bushmakin AG, Cappelleri JC, Komm BS.

Menopause. 2016 Oct;23(10):1060-6. doi: 10.1097/GME.0000000000000678.

PMID:
27404028
31.

Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data.

Constantine GD, Archer DF, Pollycove R, Jiang W, Altomare C, Pinkerton JV.

Menopause. 2016 Sep;23(9):957-64. doi: 10.1097/GME.0000000000000656.

PMID:
27404027
32.

Most bothersome symptom in women with genitourinary syndrome of menopause as a moderator of treatment effects.

Pinkerton JV, Bushmakin AG, Abraham L, Cappelleri JC, Komm BS.

Menopause. 2016 Oct;23(10):1092-101. doi: 10.1097/GME.0000000000000679.

PMID:
27404026
33.

Revised global consensus statement on menopausal hormone therapy.

de Villiers TJ, Hall JE, Pinkerton JV, Pérez SC, Rees M, Yang C, Pierroz DD.

Maturitas. 2016 Sep;91:153-5. doi: 10.1016/j.maturitas.2016.06.001. Epub 2016 Jun 16.

PMID:
27389038
34.

Revised Global Consensus Statement on Menopausal Hormone Therapy.

de Villiers TJ, Hall JE, Pinkerton JV, Cerdas Pérez S, Rees M, Yang C, Pierroz DD.

Climacteric. 2016 Aug;19(4):313-5. doi: 10.1080/13697137.2016.1196047. Epub 2016 Jun 20. No abstract available.

PMID:
27322027
35.

Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials.

Pinkerton JV, Pickar JH, Ryan KA, Yu CR, Mirkin S, Komm BS.

Menopause. 2016 Jun;23(6):611-20. doi: 10.1097/GME.0000000000000617.

PMID:
27163519
36.

Dose is important for nonhormonal therapy for hot flashes.

Pinkerton JV.

BJOG. 2016 Oct;123(11):1744. doi: 10.1111/1471-0528.14006. Epub 2016 Apr 7. No abstract available.

37.

Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.

Mirkin S, Pinkerton JV, Kagan R, Thompson JR, Pan K, Pickar JH, Komm BS, Archer DF.

J Womens Health (Larchmt). 2016 May;25(5):431-42. doi: 10.1089/jwh.2015.5351. Epub 2016 Apr 8.

PMID:
27058301
38.

Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement.

Santoro N, Braunstein GD, Butts CL, Martin KA, McDermott M, Pinkerton JV.

J Clin Endocrinol Metab. 2016 Apr;101(4):1318-43. doi: 10.1210/jc.2016-1271. Review.

PMID:
27032319
39.

Compounded non-FDA-approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey.

Pinkerton JV, Constantine GD.

Menopause. 2016 Apr;23(4):359-67. doi: 10.1097/GME.0000000000000567.

40.

Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.

Pinkerton JV, Kagan R.

Expert Opin Pharmacother. 2015;16(17):2703-14. doi: 10.1517/14656566.2015.1109627. Epub 2015 Dec 3. Review.

PMID:
26634778
41.

Inflammasomes in COPD and neutrophilic asthma.

Kim RY, Pinkerton JW, Gibson PG, Cooper MA, Horvat JC, Hansbro PM.

Thorax. 2015 Dec;70(12):1199-201. doi: 10.1136/thoraxjnl-2014-206736. Epub 2015 Oct 22. No abstract available.

PMID:
26493990
42.

Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.

Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ.

J Clin Endocrinol Metab. 2015 Nov;100(11):3975-4011. doi: 10.1210/jc.2015-2236. Epub 2015 Oct 7.

PMID:
26444994
43.

Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.

Pinkerton JV, Pickar JH.

Menopause. 2016 Feb;23(2):215-23. doi: 10.1097/GME.0000000000000523. Review.

44.

Impact of Grapevine (Vitis vinifera) Varieties on Reproduction of the Northern Root-Knot Nematode (Meloidogyne hapla).

Howland AD, Skinkis PA, Wilson JH, Riga E, Pinkerton JN, Schreiner RP, Zasada IA.

J Nematol. 2015 Jun;47(2):141-7.

45.

A short-term mouse model that reproduces the immunopathological features of rhinovirus-induced exacerbation of COPD.

Singanayagam A, Glanville N, Walton RP, Aniscenko J, Pearson RM, Pinkerton JW, Horvat JC, Hansbro PM, Bartlett NW, Johnston SL.

Clin Sci (Lond). 2015 Aug;129(3):245-58. doi: 10.1042/CS20140654.

46.

Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma.

Essilfie AT, Horvat JC, Kim RY, Mayall JR, Pinkerton JW, Beckett EL, Starkey MR, Simpson JL, Foster PS, Gibson PG, Hansbro PM.

Thorax. 2015 May;70(5):458-67. doi: 10.1136/thoraxjnl-2014-206067. Epub 2015 Mar 6.

PMID:
25746630
47.

Money talks: untreated hot flashes cost women, the workplace, and society.

Pinkerton JV.

Menopause. 2015 Mar;22(3):254-5. doi: 10.1097/GME.0000000000000427. No abstract available.

PMID:
25692878
48.

Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women.

Pinkerton JV, Santoro N.

Menopause. 2015 Sep;22(9):926-36. doi: 10.1097/GME.0000000000000420.

49.

Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence.

Archer DF, Carr BR, Pinkerton JV, Taylor HS, Constantine GD.

Menopause. 2015 Jul;22(7):786-96. doi: 10.1097/GME.0000000000000365. Review.

50.

What are the concerns about custom-compounded "bioidentical" hormone therapy?

Pinkerton JV.

Menopause. 2014 Dec;21(12):1298-300. doi: 10.1097/GME.0000000000000376.

PMID:
25387347

Supplemental Content

Loading ...
Support Center